Navigation Links
The Quigley Corporation Reports Second Quarter 2008 Results: Continues Investment in Pharmaceutical R&D Future

DOYLESTOWN, Pa., July 31 /PRNewswire-FirstCall/ -- The Quigley Corporation (Nasdaq: QGLY) today reported net sales from continuing operations of $2.1 million, for the second quarter ended June 30, 2008, compared to $2.2 million reported for the second quarter ended June 30, 2007. For the six months ended June 30, 2008, net sales were $7.4 million compared to $8.4 million reported for the six months ended June 30, 2007.

2008 net sales were influenced by distribution changes and the unusually slow start to the 2007/2008 cold season and fewer incidences of colds by consumers during much of the period. The second quarter and first six months of 2008 reflect these facts in that customer inventories remained higher than they desired, and although the cold season started to improve later in the season, it was too late to positively influence the first six months of 2008. Additionally, there was a favorable offset by a combined price increase and new products not present in the 2007 comparable periods amounting to approximately $300,000 and $1.0 million, respectively.

Loss from continuing operations for the second quarter and six months ended June 30, 2008 was $2.9 million, or ($0.22) per share, and $5.3 million, or ($0.42) per share, respectively as compared to $3.4 million, or ($0.27) per share, and $5.1 million, or ($0.40) per share, respectively for the same period in 2007.

Net loss for the second quarter and six months ended June 30, 2008 was $2.9 million, or ($0.22) per share, and $4.4 million or ($0.35) per share, respectively, compared to a net loss for the second quarter and six months ended June 30, 2007 of $3.5 million, or ($0.28) per share, and $5.4 million, or ($0.43) per share, respectively. The improvement in net loss for the six months ended June 30, 2008 reflects gains in the discontinued operations as compared to a loss for the same period in 2007.

The decrease in loss from continuing operations for the second quarter ended June 30, 2008 primarily reflects savings in operations for legal expenses and costs associated with the continued investment in Quigley Pharma, a wholly owned Ethical Pharmaceutical subsidiary developing natural-source potential prescription and other products. The overall slight increase in loss from continuing operations for the six months ended June 30, 2008 primarily reflects the reduction of gross profit from reduced sales as compared to 2007.

The Quigley Corporation continues to enhance its position to capitalize on the growth potential of Quigley Pharma by investing in key pharmaceutical research and development including QR-333, an investigational new drug for treating conditions associated with diabetic peripheral neuropathy. The Company is in the midst of Phase II (b) clinical study for QR-333, which is a key segment of the Company's strategic initiatives to generate future growth.

Over 170 million people have diabetes worldwide including an estimated 20 million people within the United States, comprising approximately 7% of the country's population. Nearly 60% of people with diabetes will suffer mild to severe nerve damage due to diabetic peripheral neuropathy, the treatment of which may offer a significant opportunity for QR-333. In addition to QR-333, The Company continues to invest in developing natural-source potential products for disease states associated with inflammation, the protection against infectious diseases in poultry products as well as protection against ionizing radiation.

No tax provision or benefits, to reduce losses, are provided for the quarter and six month period ended June 30, 2008 and 2007, since the Company is in a net operating loss carry-forward position for which a valuation has been established.

In March 2008, The Quigley Corporation completed the sale of its wholly owned subsidiary, Darius International Inc. ("Darius"), which constituted the Health and Wellness segment, to InnerLight Holdings, Inc. Net loss of the Company for the six months ended June 30, 2008 reflects results from discontinued operations associated with the sale of Darius that included a gain on disposal of $737,000 and income from discontinued operations of $139,000, totaling $876,000 as compared to a loss from discontinued operations of $390,000 for the same period in 2007.

At the end of the second quarter, The Quigley Corporation was added to the Russell Microcap(R) Index, membership in which remains in place for one year and garners automatic inclusion in the appropriate growth and value style indexes. Russell indexes are widely used by investment managers and institutional investors for index funds and an industry-leading $4.4 trillion in assets are currently benchmarked to them.

The Quigley Corporation makes no representation that the US Food and Drug Administration or any other regulatory agency will allow this Investigational New Drug to be marketed. Furthermore, no claim is made that potential medicine discussed herein is safe, effective, or approved by the Food and Drug Administration.

Additionally, data that demonstrates activity or effectiveness in animals or in vitro tests do not necessarily mean the formula test compound; referenced herein will be effective in humans. Safety and effectiveness in humans will have to be demonstrated by means of adequate and well-controlled clinical studies before the clinical significance of the formula test compound is known. Readers should carefully review the risk factors described in filings the Company files from time to time with the Securities and Exchange Commission.

About The Quigley Corporation

The Quigley Corporation (NASDAQ: QGLY, is a diversified natural health medical science company. Its Cold Remedy segment is a leading marketer and manufacturer of the COLD-EEZE(R) family of lozenges, gums and sugar free tablets clinically proven to cut the common cold nearly in half. COLD-EEZE customers include leading national wholesalers and distributors, as well as independent and chain food, drug and mass merchandise stores and pharmacies. The Quigley Corporation has wholly owned subsidiaries; Quigley Manufacturing Inc. consists of two FDA approved facilities to manufacture COLD- EEZE(R) lozenges as well as fulfill other contract manufacturing opportunities and Quigley Pharma Inc. ( conducts research in order to develop and commercialize a pipeline of patented botanical and naturally derived potential prescription drugs.

Forward-Looking Statements

Certain statements in this press release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and involve known and unknown risk, uncertainties and other factors that may cause the Company's actual performance or achievements to be materially different from the results, performance or achievements expressed or implied by the forward-looking statement. Factors that impact such forward-looking statements include, among others, changes in worldwide general economic conditions, changes in interest rates, government regulations, and worldwide competition.


George J. Longo Carl Hymans

Vice President, CFO G.S. Schwartz & Co.

(215) 345-0919 (212) 725-4500

Consolidated Statements of Operations (Unaudited)

The following represents condensed financial data (in thousands) except per share data:

Three-Months Three-Months Six-Months Six-Months

Ended Ended Ended Ended

June 30, June 30, June 30, June 30,

2008 2007 2008 2007

($) ($) ($) ($)

Net Sales 2,068 2,217 7,373 8,367

Gross profit 898 995 4,467 4,934

Sales & marketing expenses 566 556 2,799 3,046

Administrative expenses 2,030 2,436 4,538 4,582

Research & development 1,265 1,622 2,675 2,774

Income taxes (benefit) - - - -

Income (Loss) from:

Continuing operations (2,879) (3,417) (5,324) (5,058)

Discontinued operations - (103) 876 (390)

Net Income (Loss) (2,879) (3,520) (4,448) (5,448)

Diluted income (loss)

per share:

Continuing operations ($0.22) ($0.27) ($0.42) ($0.40)

Discontinued operations - (0.01) 0.07 (0.03)

Net loss ($0.22) ($0.28) ($0.35) ($0.43)

Diluted weighted average

common shares

outstanding: 12,861,800 12,684,633 12,860,616 12,684,633

Consolidated Balance Sheets (Unaudited)

The following represents condensed financial data (in thousands) at June 30, 2008 and December 31, 2007:

2008 2007

($) ($)

Cash & cash equivalents 14,375 15,134

Accounts receivable, net 1,613 6,649

Inventory 4,621 4,136

Total current assets 21,486 28,835

Total assets 25,557 33,502

Total current liabilities 6,749 10,258

Total stockholders' equity 18,808 23,244

SOURCE Quigley Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Quigley Corporation Releases Update on Quigley Pharmas Phase IIb Clinical Study of QR-333 in Diabetic Peripheral Neuropathy
2. Volcano Corporation Schedules Second Quarter Conference Call, Webcast
3. Roche and Response Biomedical Corporation Aim to Reduce Vein-to-Brain Time with New Point-of-Care Cardiac Tests
4. CorVel Corporation Announces Earnings Release Webcast
5. Genzyme Corporation and PTC Therapeutics Announce Collaboration on Small Molecule for Genetic Diseases
6. Webcast Alert: Neogen Corporation Announces Year-End Results
7. PURE Bioscience Announces Distribution Agreement With Orchem Corporation
8. Sigma-Aldrich Corporations 2nd Quarter 2008 Earnings Conference Call
9. Genaera Corporation Elects Paul K. Wotton to Board of Directors
10. BioTime, Inc. and Embryome Sciences, Inc. Sign Agreement With International Stem Cell Corporation to Provide Unique Human Stem Cell Lines for Research Use
11. U.S. Commerce Secretary Gutierrez Cuts Ribbon on MaxWell Biocorporations New Pharmaceutical Development Center and Quality Control Laboratory in Ukraine
Post Your Comments:
(Date:12/1/2015)... 1, 2015 Vancouver ... lancet that features Owen Mumford,s unique Comfort Zone Technology®. ... Unistik® Touch is a touch activated lancet that features ... Owen Mumford, a leading medical device manufacturer, today unveils ... available initially in the US before expanding out to ...
(Date:12/1/2015)... , Dec. 1, 2015 Today the ... in Seattle,s South Lake Union ... corner of Mercer Street and Westlake Avenue North, the ... the Allen Institute for Brain Science and the Allen ... , philanthropist and founder of the Allen Institute. "We ...
(Date:12/1/2015)... Dec. 1, 2015 Researchers at the Broad ... for Brain Research at MIT have engineered changes to ... down on "off-target" editing errors. The refined technique addresses ... of genome editing. Science , Feng ... of the approximately 1,400 amino acids that make up ...
(Date:12/1/2015)... Bioscience, a company focused on synthetic DNA, today announced that ... as one of Foreign Policy,s 100 Leading Global ... life . Each year, Foreign Policy selects the ... changed lives and are shaping the world. ... be recognized among these incredible global leaders," said Leproust. "At ...
Breaking Biology Technology:
(Date:12/1/2015)... Synaptics Incorporated (NASDAQ: SYNA ), the ... new agreement with Nok Nok Labs ™ ... environments that combine FIDO Certified ™ Synaptics and ... of FIDO certification for Synaptics, customers. Using Nok Nok ... verify FIDO enabled devices in real-world authentication scenarios. ...
(Date:11/30/2015)... , Nov. 30, 2015  BIOCLAIM announced ... finalist in this year,s Fierce Innovation Awards:  Healthcare Edition, ... FierceHealthIT , FierceHealthcare , ... as a finalist in the category of "Privacy ... --> --> ...
(Date:11/26/2015)... 26, 2015 Research and Markets ( ... Fingerprint Sensors - Technology and Patent Infringement Risk Analysis" ... --> --> Fingerprint sensors using capacitive ... The fingerprint sensor vendor Idex forecasts an increase of ... mobile devices and of the fingerprint sensor market between ...
Breaking Biology News(10 mins):